Hearing in October on Hi-Tech's generic exclusivity on Cosopt
This article was originally published in Scrip
Executive Summary
Hi-Tech Pharmacal has filed a complaint against the US FDArequesting a declaratory judgement relating to the company's ANDA for a generic version of Merck & Co's Cosopt (dorzolamide plus timolol ophthalmic solution). Hi-Tech seeks confirmation that it is entitled to 180 days of exclusivity as the first applicant to submit an ANDA containing a paragraph IV certification challenging the validity of the Orange Book-listed patents for Cosopt.